OncoCyte Corporation (NASDAQ: OCX) reported Q3 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.65 million.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.